Pemetrexed EVER Pharma 25 mg/ml concentrate for solution for infusion

DRUG2 trials

Sponsors

Oncomatryx Biopharma S.L., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.

Conditions

Advanced/Metastatic Non-squamous Non-Small Cell Lung Cancerlocally advanced or metastatic NSCLC

Phase 1

Phase 1b/2 Trial of OMTX705, an Anti-Fibroblast Activation Protein Antibody-Drug Conjugate, in Combination with Carboplatin, Pemetrexed and Tislelizumab in Patients with Advanced/Metastatic Non-squamous Non-Small Cell Lung Cancer

Not yet recruitingCTIS2025-521989-95-00

Oncomatryx Biopharma S.L.Advanced/Metastatic Non-squamous Non-Small Cell Lung Cancer

Target: 88Updated: 2025-12-12

Phase 2

Beamion 44: A randomized, open-label, multi-center Phase IIa platform trial to evaluate the safety and tolerability of zongertinib plus Pt-doublet with or without pembrolizumab (and potential other combinations) in treatment-naïve patients with locally advanced/metastatic non-squamous NSCLC with activating HER2 mutations

Not yet recruitingCTIS2025-523567-38-00

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.locally advanced or metastatic NSCLC

Target: 11Updated: 2026-05-19